RATIONALE: Several lines of evidence suggest inter-dependency between the serotonin transporter (5-HTT) and the 5HT1A receptor, two recognised targets for the treatment of anxiety and depression. OBJECTIVES: to examine the correlation of regional expression levels for these two serotonergic markers in the human brain in vivo. METHODS: Twelve male control subjects were examined with PET twice on the same day, using the radioligands [11C]WAY 100635 and [11C]MADAM for quantification of the 5-HT1A receptor and the 5-HTT, respectively. The binding potential (BP) was calculated for raphe nuclei, hippocampus and frontal cortex. RESULTS: In all regions, the BP for both [11C]WAY 100635 (raphe nuclei 1.85-4.71, hippocampus 2.52-6.17, frontal cortex 2.03-3.79) and [11C]MADAM (2.70-7.65, 0.47-1.76, 0.18-0.51) varied several fold between subjects. In the raphe nuclei, where the two markers are situated on the same neurons, the ratio of [11C]WAY 100635 binding to [11C]MADAM BP binding varied considerably (0.43-1.05). There was a positive correlation between the two markers in the raphe nuclei (rxy=0.68, p<0.05) and in the hippocampus (rxy=0.97, p<0.001) but not in the frontal cortex (rxy=-0.25, p=0.44). CONCLUSIONS: The results support a correlation between density levels of the 5-HT1A-receptor and the 5-HTT in the raphe nuclei and hippocampus but not in the frontal cortex. A suggested clinical implication is that the inter-individual variability in 5-HT1A-receptor and 5-HTT densities, as well as the ratio of these, is of particular interest in relation to individual responses to selective serotonin reuptake inhibitor treatment.
RATIONALE: Several lines of evidence suggest inter-dependency between the serotonin transporter (5-HTT) and the 5HT1A receptor, two recognised targets for the treatment of anxiety and depression. OBJECTIVES: to examine the correlation of regional expression levels for these two serotonergic markers in the human brain in vivo. METHODS: Twelve male control subjects were examined with PET twice on the same day, using the radioligands [11C]WAY 100635 and [11C]MADAM for quantification of the 5-HT1A receptor and the 5-HTT, respectively. The binding potential (BP) was calculated for raphe nuclei, hippocampus and frontal cortex. RESULTS: In all regions, the BP for both [11C]WAY 100635 (raphe nuclei 1.85-4.71, hippocampus 2.52-6.17, frontal cortex 2.03-3.79) and [11C]MADAM (2.70-7.65, 0.47-1.76, 0.18-0.51) varied several fold between subjects. In the raphe nuclei, where the two markers are situated on the same neurons, the ratio of [11C]WAY 100635 binding to [11C]MADAM BP binding varied considerably (0.43-1.05). There was a positive correlation between the two markers in the raphe nuclei (rxy=0.68, p<0.05) and in the hippocampus (rxy=0.97, p<0.001) but not in the frontal cortex (rxy=-0.25, p=0.44). CONCLUSIONS: The results support a correlation between density levels of the 5-HT1A-receptor and the 5-HTT in the raphe nuclei and hippocampus but not in the frontal cortex. A suggested clinical implication is that the inter-individual variability in 5-HT1A-receptor and 5-HTT densities, as well as the ratio of these, is of particular interest in relation to individual responses to selective serotonin reuptake inhibitor treatment.
Authors: Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann Journal: Biol Psychiatry Date: 2005-09-09 Impact factor: 13.382
Authors: W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis Journal: Biol Psychiatry Date: 1999-11-15 Impact factor: 13.382
Authors: Carolyn Cidis Meltzer; Julie C Price; Chester A Mathis; Meryl A Butters; Scott K Ziolko; Eydie Moses-Kolko; Sati Mazumdar; Benoit H Mulsant; Patricia R Houck; Brian J Lopresti; Lisa A Weissfeld; Charles F Reynolds Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: Sean P David; Naga Venkatesha Murthy; Eugenii A Rabiner; Marcus R Munafó; Elaine C Johnstone; Robyn Jacob; Robert T Walton; Paul M Grasby Journal: J Neurosci Date: 2005-03-09 Impact factor: 6.167
Authors: Lauri Tuominen; Lauri Nummenmaa; Liisa Keltikangas-Järvinen; Olli Raitakari; Jarmo Hietala Journal: Hum Brain Mapp Date: 2013-05-14 Impact factor: 5.038
Authors: Johan Lundberg; Mikael Tiger; Mikael Landén; Christer Halldin; Lars Farde Journal: Int J Neuropsychopharmacol Date: 2012-01-16 Impact factor: 5.176
Authors: Michael Strupp-Levitsky; Jeffrey M Miller; Harry Rubin-Falcone; Francesca Zanderigo; Matthew S Milak; Gregory Sullivan; R Todd Ogden; Maria A Oquendo; Christine DeLorenzo; Norman Simpson; Ramin V Parsey; J John Mann Journal: Psychiatry Res Neuroimaging Date: 2016-08-08 Impact factor: 2.376
Authors: M Embree; V Michopoulos; J R Votaw; R J Voll; J Mun; J S Stehouwer; M M Goodman; M E Wilson; M M Sánchez Journal: Neuroscience Date: 2012-10-16 Impact factor: 3.590
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944